Cost-Effectiveness of Dementia Prevention Interventions

J Prev Alzheimers Dis. 2021;8(2):210-217. doi: 10.14283/jpad.2020.71.

Abstract

Background: Assessment of cost-effectiveness of interventions to address modifiable risk factors associated with dementia requires estimates of long-term impacts of these interventions which are rarely directly available and must be estimated using a range of assumptions.

Objectives: To test the cost-effectiveness of dementia prevention measures using a methodology which transparently addresses the many assumptions required to use data from short-term studies, and which readily incorporates sensitivity analyses.

Design: We explore an approach to estimating cost-effective prices which uses aggregate data including estimated lifetime costs of dementia, both financial and quality of life, and incorporates a range of assumptions regarding sustainability of short- term gains and other parameters.

Setting: The approach is addressed in the context of the theoretical reduction in a range of risk factors, and in the context of a specific small-scale trial of an internet-based intervention augmented with diet and physical activity consultations.

Measurements: The principal outcomes were prices per unit of interventions at which interventions were cost-effective or cost-saving.

Results: Taking a societal perspective, a notional intervention reducing a range of dementia risk-factors by 5% was cost-effective at $A460 per person with higher risk groups at $2,148 per person. The on-line program costing $825 per person was cost-effective at $1,850 per person even if program effect diminished by 75% over time.

Conclusions: Interventions to address risk factors for dementia are likely to be cost-effective if appropriately designed, but confirmation of this conclusion requires longer term follow-up of trials to measure the impact and sustainability of short-term gains.

Keywords: Dementia; cost-effectiveness; interventions; risk factors; sustainability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost-Benefit Analysis*
  • Delivery of Health Care / economics*
  • Dementia / drug therapy
  • Dementia / economics*
  • Exercise / physiology
  • Health Care Costs*
  • Humans
  • Quality of Life